{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:26:57Z","timestamp":1793064417117,"version":"4.5.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>We present our experience with MR-guided stereotactic body radiotherapy (SBRT) for 200 consecutive patients with prostate cancer with minimum 3-month follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Treatment planning included fusion of the 0.35-Tesla planning MRI with multiparametric MRI and PET-PSMA for Group Grade (GG) 2 or higher and contour review with an expert MRI radiologist. No fiducials or rectal spacers were used. Prescription dose was 36.25 Gy in 5 fractions over 2 weeks to the entire prostate with 3-mm margins. Daily plan was adapted if tumor and organs at risk (OAR) doses differed significantly from the original plan. The prostate was monitored during treatment that was automatically interrupted if the target moved out of the PTV range.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean age was 72 years. Clinical stage was T1c, 85.5%; T2, 13%; and T3, 1.5%. In addition, 20% were GG1, 50% were GG2, 14.5% were GG3, 13% were GG4, and one patient was GG5. PSA ranged from 1 to 77 (median, 6.2). Median prostate volume was 57cc, and 888\/1000 (88%) fractions required plan adaptation. The most common acute GU toxicity was Grade I, 31%;\u00a0dysuria and acute\u00a0gastrointestinal toxicity were rare. Three patients required temporary catheterization. Prostate size of over 100cc was associated with acute fatigue, urinary hesitance, and catheter insertion. Prostate Specific Antigen (PSA) decreased in 99% of patients, and one patient had regional recurrence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MR-guided prostate SBRT shows low acute toxicity and excellent short-term outcomes. Real-time MRI ensures accurate positioning and SBRT delivery.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1151256","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T07:32:09Z","timestamp":1679556729000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Outcome of the first 200 patients with prostate cancer treated with MRI-Linac at Assuta MC"],"prefix":"10.3389","volume":"13","author":[{"given":"Or","family":"Gelbart Pridan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav Akiva","family":"Ben David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Zalmanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Lipski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladislav","family":"Grinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Apter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Guindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Radus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Arsenault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Hod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qusai","family":"Tamami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/CAAC.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-95693-0_1","article-title":"Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies","volume":"1095","author":"Schatten","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2016.04.014","article-title":"MRI-Guided prostate adaptive radiotherapy - a systematic review","volume":"119","author":"McPartlin","year":"2016","journal-title":"Radiother Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejca.2019.07.021","article-title":"MR linac Atlantic consortium and the ViewRay C2T2 research consortium. the transformation of radiation oncology using real-time magnetic resonance guidance: A review","volume":"122","author":"Hall","year":"2019","journal-title":"Eur J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.11.047","article-title":"Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer","volume":"84","author":"Zelefsky","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13014-020-01604-5","article-title":"Dosimetric effects of adaptive prostate cancer radiotherapy in an MR-linac workflow","volume":"15","author":"Mannerberg","year":"2020","journal-title":"Radiat Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.phro.2019.02.002","article-title":"Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer","volume":"9","author":"Tetar","year":"2019","journal-title":"Phys Imaging Radiat Oncol"},{"key":"B9","unstructured":"Common terminology criteria for adverse events (CTCAE)2017"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.07.003","article-title":"Patterns of care, tolerability, and safety of the first cohort of patients treated on a novel high-field MR-linac within the MOMENTUM study: Initial results from a prospective multi-institutional registry","volume":"111","author":"de Mol van Otterloo","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJROBP.2019.08.007","article-title":"A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: Early toxicity results","volume":"105","author":"Bruynzeel","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1259\/bjr.20200696","article-title":"Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: Preliminary results of outcome and toxicity","volume":"1","author":"Ugurluer","year":"2021","journal-title":"The British Journal of Radiology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: The MIRAGE randomized clinical trial","volume":"12","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-b): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJROBP.2011.02.037","article-title":"Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis","volume":"81","author":"Zilli","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1259\/BJR.20160348","article-title":"Simple diagrammatic method to delineate male urethra in prostate cancer radiotherapy: an MRI based approach","volume":"89","author":"Kataria","year":"2016","journal-title":"Br J Radiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/S13014-020-01510-W","article-title":"1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment","volume":"15","author":"Alongi","year":"2020","journal-title":"Radiat Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/J.EUO.2020.05.007","article-title":"Magnetic resonance-guided stereotactic radiotherapy for localized prostate cancer: Final results on patient-reported outcomes of a prospective phase 2 study","volume":"4","author":"Tetar","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/J.IJROBP.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: Survival and toxicity endpoints","volume":"102","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJROBP.2013.10.042","article-title":"Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"88","author":"Ghadjar","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJROBP.2015.04.030","article-title":"Hydrogel spacer prospective multicenter randomized controlled pivotal trial: Dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy","volume":"92","author":"Mariados","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70482-6","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial","volume":"16","author":"Aluwini","year":"2015","journal-title":"Articles Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/S13014-017-0884-Y","article-title":"Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation","volume":"12","author":"Geara","year":"2017","journal-title":"Radiat Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJROBP.2005.07","article-title":"PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis","volume":"64","author":"Ray","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1151256\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T07:32:14Z","timestamp":1679556734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1151256\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":25,"alternative-id":["10.3389\/fonc.2023.1151256"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1151256","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"article-number":"1151256"}}